ES2532497T3 - Uso de acetil-L-carnitina para la preparación de un medicamento para el tratamiento del dolor neuropático en pacientes diabéticos - Google Patents
Uso de acetil-L-carnitina para la preparación de un medicamento para el tratamiento del dolor neuropático en pacientes diabéticos Download PDFInfo
- Publication number
- ES2532497T3 ES2532497T3 ES05730316.6T ES05730316T ES2532497T3 ES 2532497 T3 ES2532497 T3 ES 2532497T3 ES 05730316 T ES05730316 T ES 05730316T ES 2532497 T3 ES2532497 T3 ES 2532497T3
- Authority
- ES
- Spain
- Prior art keywords
- patients
- carnitine
- acetyl
- treatment
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 8
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 206010012601 diabetes mellitus Diseases 0.000 title description 28
- 229940079593 drug Drugs 0.000 title description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 36
- 102000004877 Insulin Human genes 0.000 claims abstract description 18
- 108090001061 Insulin Proteins 0.000 claims abstract description 18
- 229940125396 insulin Drugs 0.000 claims abstract description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000002253 acid Substances 0.000 claims description 22
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- -1 mucate Substances 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 claims description 2
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229940095060 magnesium tartrate Drugs 0.000 claims description 2
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims description 2
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims description 2
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 25
- 230000006872 improvement Effects 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 22
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 21
- 201000001421 hyperglycemia Diseases 0.000 description 14
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 208000033808 peripheral neuropathy Diseases 0.000 description 8
- 230000002093 peripheral effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 5
- 206010036105 Polyneuropathy Diseases 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000007824 polyneuropathy Effects 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008094 contradictory effect Effects 0.000 description 2
- 201000002342 diabetic polyneuropathy Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000327A ITRM20040327A1 (it) | 2004-07-01 | 2004-07-01 | Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici. |
| ITRM20040327 | 2004-07-01 | ||
| PCT/EP2005/003557 WO2006002698A1 (en) | 2004-07-01 | 2005-04-05 | Use of acetyl l-carnitine for the preparation of a medicine for the treatment of neuropathic pain in diabetic patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2532497T3 true ES2532497T3 (es) | 2015-03-27 |
Family
ID=34965656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05730316.6T Expired - Lifetime ES2532497T3 (es) | 2004-07-01 | 2005-04-05 | Uso de acetil-L-carnitina para la preparación de un medicamento para el tratamiento del dolor neuropático en pacientes diabéticos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20060004095A1 (enExample) |
| EP (1) | EP1761257B1 (enExample) |
| JP (1) | JP5519907B2 (enExample) |
| KR (1) | KR101176347B1 (enExample) |
| CA (1) | CA2570268C (enExample) |
| CY (1) | CY1116171T1 (enExample) |
| DK (1) | DK1761257T3 (enExample) |
| ES (1) | ES2532497T3 (enExample) |
| IT (1) | ITRM20040327A1 (enExample) |
| MX (1) | MXPA06014907A (enExample) |
| PL (1) | PL1761257T3 (enExample) |
| PT (1) | PT1761257E (enExample) |
| SI (1) | SI1761257T1 (enExample) |
| WO (1) | WO2006002698A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230002B1 (en) * | 2000-12-15 | 2015-04-28 | Sigma Tau Ind Farmaceuti | Use of l-carnitine for preparation of compositions for stabilizing the proteins |
| US8173618B2 (en) * | 2003-07-25 | 2012-05-08 | University Of Massachusetts | Formulations for reducing neuronal degeneration |
| US8597640B2 (en) * | 2007-10-31 | 2013-12-03 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1133010B (it) * | 1980-05-15 | 1986-07-09 | Sigma Tau Ind Farmaceuti | Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo |
| IT1196564B (it) * | 1986-08-04 | 1988-11-16 | Sigma Tau Ind Farmaceuti | Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche |
| IT1224842B (it) * | 1988-12-27 | 1990-10-24 | Sigma Tau Ind Farmaceuti | Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso |
| IT1263004B (it) * | 1992-10-08 | 1996-07-23 | Sigma Tau Ind Farmaceuti | Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti. |
| US5827886A (en) * | 1997-05-07 | 1998-10-27 | Thione International, Inc. | Composition for relief of arthritis-induced symptoms |
| IT1294227B1 (it) * | 1997-08-01 | 1999-03-24 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione |
| IT1306178B1 (it) * | 1999-07-27 | 2001-05-30 | Sigma Tau Ind Farmaceuti | Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento utile nel trattamento del paziente affetto da |
| ITRM20010294A1 (it) * | 2001-05-29 | 2002-11-29 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re |
-
2004
- 2004-07-01 IT IT000327A patent/ITRM20040327A1/it unknown
- 2004-10-21 US US10/969,217 patent/US20060004095A1/en not_active Abandoned
-
2005
- 2005-04-05 SI SI200531946T patent/SI1761257T1/sl unknown
- 2005-04-05 PT PT57303166T patent/PT1761257E/pt unknown
- 2005-04-05 KR KR1020077000584A patent/KR101176347B1/ko not_active Expired - Fee Related
- 2005-04-05 PL PL05730316T patent/PL1761257T3/pl unknown
- 2005-04-05 WO PCT/EP2005/003557 patent/WO2006002698A1/en not_active Ceased
- 2005-04-05 JP JP2007519628A patent/JP5519907B2/ja not_active Expired - Fee Related
- 2005-04-05 CA CA2570268A patent/CA2570268C/en not_active Expired - Lifetime
- 2005-04-05 US US11/570,484 patent/US20070213408A1/en not_active Abandoned
- 2005-04-05 DK DK05730316T patent/DK1761257T3/en active
- 2005-04-05 ES ES05730316.6T patent/ES2532497T3/es not_active Expired - Lifetime
- 2005-04-05 EP EP05730316.6A patent/EP1761257B1/en not_active Expired - Lifetime
- 2005-04-05 MX MXPA06014907A patent/MXPA06014907A/es not_active Application Discontinuation
-
2015
- 2015-03-23 CY CY20151100283T patent/CY1116171T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2570268C (en) | 2013-10-15 |
| JP5519907B2 (ja) | 2014-06-11 |
| SI1761257T1 (sl) | 2015-04-30 |
| ITRM20040327A1 (it) | 2004-10-01 |
| EP1761257A1 (en) | 2007-03-14 |
| DK1761257T3 (en) | 2015-03-23 |
| PT1761257E (pt) | 2015-04-14 |
| KR20070042963A (ko) | 2007-04-24 |
| MXPA06014907A (es) | 2007-03-21 |
| CA2570268A1 (en) | 2006-01-12 |
| CY1116171T1 (el) | 2017-02-08 |
| WO2006002698A1 (en) | 2006-01-12 |
| JP2008505134A (ja) | 2008-02-21 |
| EP1761257B1 (en) | 2014-12-31 |
| US20060004095A1 (en) | 2006-01-05 |
| KR101176347B1 (ko) | 2012-08-24 |
| PL1761257T3 (pl) | 2015-06-30 |
| US20070213408A1 (en) | 2007-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bolton | Neuromuscular manifestations of critical illness | |
| Kongkam et al. | Propofol infusion versus intermittent meperidine and midazolam injection for conscious sedation in ERCP | |
| KR960705556A (ko) | 비타민 k를 사용하여 피부의 혈관 질환을 처치하는 방법 및 조성물(composition and method for treating blood vessel disorders of the skin using vitamin k) | |
| BR112020002244A2 (pt) | aminoácidos de cadeia ramificada para o tratamento de lesão neurológica | |
| CA2389623A1 (en) | Method of treating benign forgetfulness | |
| ES2797688T3 (es) | Arginina silicato inositol para mejorar la función cognitiva | |
| EP3544603A2 (en) | Prevention and/or treatment of chronic fatigue syndrome | |
| JP4276779B2 (ja) | 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用 | |
| ES2925775T3 (es) | Esteres de ácido azelaico en el tratamiento de la resistencia a la insulina | |
| ES2532497T3 (es) | Uso de acetil-L-carnitina para la preparación de un medicamento para el tratamiento del dolor neuropático en pacientes diabéticos | |
| US20080161604A1 (en) | Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy | |
| ES2268053T3 (es) | Uso de acetil l-carnitina en asociacion con biotina para el tratamiento de pacientes con diabetes mellitus de tipo 2 resistente a insulina. | |
| US8952059B2 (en) | Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes | |
| ES2425045T3 (es) | Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa | |
| Kawano et al. | ST-segment elevation of electrocardiogram in a patient with Shoshin beriberi | |
| ES2608398T3 (es) | Utilización de hierro para el tratamiento del trastorno del déficit de atención/hiperactividad en niños | |
| JP5685362B2 (ja) | 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン | |
| ES2320788T3 (es) | Uso de l-acetilcarnitina para el tratamiento del sindrome fibromialgico. | |
| Sharda | A Study on the Role of Omega Fatty Acids as an Adjuvant Therapy in Treatment of Amblyopia | |
| Roshanzamiri et al. | Serotonin Syndrome due to Concomitant use of Linezolid and Methadone | |
| PT2229943E (pt) | Composto para ser utilizado no tratamento das neuropatias periféricas. | |
| PT1399143E (pt) | Utilização da acetil-l-carnitina na preparação de um medicamento para tratar a anedonia | |
| Nylen | The role of acetone in the anticonvulsant actions of the ketogenic diet in rats | |
| UA144584U (uk) | Спосіб профілактики та лікування цукрового діабету 2-го типу шляхом корекції дефіциту магнію в організмі | |
| McCarron | Annotated Abstracts |